Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8888745 | ORGANON | Applicator for inserting an implant |
Aug, 2026
(2 years from now) | |
US10821277 | ORGANON | Kit for and method of assembling an applicator for inserting an implant |
May, 2027
(3 years from now) | |
US8722037 | ORGANON | X-ray visible drug delivery device |
Sep, 2027
(4 years from now) | |
US9757552 | ORGANON | Applicator for inserting an implant |
Jul, 2030
(6 years from now) |
Drugs and Companies using ETONOGESTREL ingredient
Market Authorisation Date: 17 July, 2006
Treatment: Prevention of pregnancy
Dosage: IMPLANT;IMPLANTATION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8007830 | ORGANON | Granule formation |
Oct, 2022
(11 months ago) |
Drugs and Companies using MONTELUKAST SODIUM ingredient
Market Authorisation Date: 26 July, 2002
Treatment: NA
Dosage: GRANULE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7030106 | ORGANON | Sterol absorption inhibitor compositions |
Jan, 2022
(1 year, 8 months ago) | |
US7030106 (Pediatric) | ORGANON | Sterol absorption inhibitor compositions |
Jul, 2022
(1 year, 2 months ago) | |
US7612058 | ORGANON | Methods for inhibiting sterol absorption |
Oct, 2025
(2 years from now) | |
US7612058 (Pediatric) | ORGANON | Methods for inhibiting sterol absorption |
Apr, 2026
(2 years from now) |
Drugs and Companies using EZETIMIBE ingredient
Market Authorisation Date: 25 October, 2002
Treatment: To reduce elevated total-c, ldl-c, apo b and non-hdl-c in patients with primary hyperlipidemia by administration of ezetimibe alone or in combination with a statin or with fenofibrate; Reduction of el...
Dosage: TABLET;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic